#yahoofinance #teva #pharmaceutical #earnings

Teva Pharmaceuticals second quarter earnings beat analust estimates, seeing a boost in revenue thanks to its name-brand drugs. What has Teva Pharmaceuticals CEO Richard Francis excited though are the prospects for three brand name drugs, including migraine drug Ajovy. However, Francis notes the company has some work to do to win over investors. One of the issues has been struggling with is a shortage of workers. Francis says "we actually are hiring, and we are finding it competitive still, but I think Teva has good value proposition," for potential employees. One of things the company has been battling with is a variety of lawsuits, including ones stemming from the opioid epidemic. Francis says of the company's legal woes, "we are coming out of that litigation, so I think that litigation is behind us and what we're now doing is focusing on growth." This segment aired August 2, 2023.

Subscribe to Yahoo Finance: https://yhoo.it/2fGu5Bb

About Yahoo Finance:
At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Yahoo Finance Plus: With a subscription to Yahoo Finance Plus get the tools you need to invest with confidence. Discover new opportunities with expert research and investment ideas backed by technical and fundamental analysis. Optimize your trades with advanced portfolio insights, fundamental analysis, enhanced charting, and more.
To learn more about Yahoo Finance Plus please visit: https://yhoo.it/33jXYBp

Connect with Yahoo Finance:
Get the latest news: https://yhoo.it/2fGu5Bb
Find Yahoo Finance on Facebook: http://bit.ly/2A9u5Zq
Follow Yahoo Finance on Twitter: http://bit.ly/2LMgloP
Follow Yahoo Finance on Instagram: http://bit.ly/2LOpNYz
Follow Yahoo Finance Premium on Twitter: https://bit.ly/3hhcnmV